| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 21 | 2021 | 313 | 2.700 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 12 | 2013 | 16 | 2.410 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 12 | 2013 | 17 | 2.360 |
Why?
|
| Biomarkers, Tumor | 16 | 2020 | 415 | 1.900 |
Why?
|
| Glioma | 13 | 2021 | 122 | 1.860 |
Why?
|
| Adenocarcinoma | 7 | 2019 | 300 | 1.430 |
Why?
|
| Immunohistochemistry | 25 | 2021 | 465 | 1.350 |
Why?
|
| Pancreatic Neoplasms | 8 | 2022 | 548 | 0.980 |
Why?
|
| Humans | 96 | 2022 | 28906 | 0.920 |
Why?
|
| Urinary Bladder | 10 | 2018 | 119 | 0.880 |
Why?
|
| Neuroectodermal Tumors, Primitive | 4 | 2015 | 10 | 0.820 |
Why?
|
| Prostatic Neoplasms | 9 | 2019 | 302 | 0.810 |
Why?
|
| Lung Neoplasms | 4 | 2016 | 360 | 0.740 |
Why?
|
| Regeneration | 12 | 2020 | 77 | 0.740 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 12 | 2017 | 21 | 0.720 |
Why?
|
| Glioblastoma | 5 | 2021 | 109 | 0.700 |
Why?
|
| Sarcoma, Ewing | 2 | 2015 | 15 | 0.670 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 25 | 0.650 |
Why?
|
| Cerebellar Neoplasms | 4 | 2019 | 30 | 0.650 |
Why?
|
| Medulloblastoma | 3 | 2015 | 20 | 0.630 |
Why?
|
| Carcinoma | 2 | 2021 | 74 | 0.580 |
Why?
|
| Male | 42 | 2021 | 13946 | 0.580 |
Why?
|
| Cerebral Ventricle Neoplasms | 3 | 2019 | 8 | 0.580 |
Why?
|
| Melanoma | 3 | 2014 | 140 | 0.560 |
Why?
|
| Animals | 45 | 2022 | 10705 | 0.550 |
Why?
|
| Female | 44 | 2021 | 15649 | 0.550 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 483 | 0.530 |
Why?
|
| Third Ventricle | 2 | 2014 | 9 | 0.520 |
Why?
|
| Intestine, Small | 7 | 2018 | 66 | 0.520 |
Why?
|
| Neuroendocrine Tumors | 2 | 2015 | 29 | 0.520 |
Why?
|
| Cell Line, Tumor | 21 | 2022 | 1351 | 0.520 |
Why?
|
| Neoplasms, Neuroepithelial | 2 | 2018 | 9 | 0.510 |
Why?
|
| Mutation | 9 | 2021 | 867 | 0.480 |
Why?
|
| Ependymoma | 2 | 2014 | 12 | 0.480 |
Why?
|
| Intestinal Mucosa | 6 | 2018 | 198 | 0.480 |
Why?
|
| Biocompatible Materials | 5 | 2020 | 95 | 0.470 |
Why?
|
| Brain | 2 | 2021 | 770 | 0.460 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 3 | 2021 | 26 | 0.460 |
Why?
|
| Urothelium | 5 | 2018 | 35 | 0.450 |
Why?
|
| Tissue Scaffolds | 5 | 2021 | 89 | 0.450 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 79 | 0.450 |
Why?
|
| Meningioma | 2 | 2020 | 79 | 0.450 |
Why?
|
| Palatal Neoplasms | 1 | 2014 | 2 | 0.450 |
Why?
|
| Palate, Hard | 1 | 2014 | 2 | 0.450 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2012 | 29 | 0.450 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 147 | 0.450 |
Why?
|
| Prostate | 6 | 2019 | 52 | 0.450 |
Why?
|
| Oncogene Proteins, Fusion | 5 | 2017 | 25 | 0.440 |
Why?
|
| Cell Proliferation | 16 | 2022 | 825 | 0.440 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 103 | 0.440 |
Why?
|
| Rhabdoid Tumor | 2 | 2004 | 9 | 0.440 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2014 | 22 | 0.440 |
Why?
|
| Computer-Assisted Instruction | 2 | 2012 | 32 | 0.430 |
Why?
|
| Apoptosis | 8 | 2017 | 780 | 0.430 |
Why?
|
| Aged | 17 | 2021 | 5604 | 0.420 |
Why?
|
| Middle Aged | 20 | 2021 | 7419 | 0.420 |
Why?
|
| Prognosis | 12 | 2021 | 811 | 0.410 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2013 | 7 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 6 | 2021 | 336 | 0.400 |
Why?
|
| Boswellia | 4 | 2016 | 4 | 0.390 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2013 | 41 | 0.390 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2019 | 843 | 0.380 |
Why?
|
| Signal Transduction | 13 | 2021 | 1469 | 0.380 |
Why?
|
| Adult | 20 | 2021 | 8037 | 0.380 |
Why?
|
| Esophagogastric Junction | 1 | 2012 | 6 | 0.370 |
Why?
|
| Mice | 21 | 2022 | 4809 | 0.370 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2012 | 9 | 0.370 |
Why?
|
| Pinealoma | 1 | 2012 | 4 | 0.370 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2012 | 14 | 0.370 |
Why?
|
| Swine | 13 | 2022 | 238 | 0.370 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 11 | 0.360 |
Why?
|
| Internet | 2 | 2012 | 126 | 0.360 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 33 | 0.360 |
Why?
|
| Hyaluronic Acid | 4 | 2021 | 103 | 0.360 |
Why?
|
| Stress, Mechanical | 3 | 2021 | 115 | 0.350 |
Why?
|
| Cachexia | 2 | 2022 | 53 | 0.350 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 2065 | 0.350 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2021 | 87 | 0.350 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2017 | 20 | 0.350 |
Why?
|
| Education, Medical | 1 | 2012 | 68 | 0.340 |
Why?
|
| Endometrial Hyperplasia | 1 | 2010 | 6 | 0.330 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 165 | 0.330 |
Why?
|
| Cation Transport Proteins | 3 | 2021 | 60 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 472 | 0.320 |
Why?
|
| Neurilemmoma | 1 | 2010 | 13 | 0.320 |
Why?
|
| Neovascularization, Pathologic | 3 | 2017 | 148 | 0.320 |
Why?
|
| Aortic Valve | 2 | 2021 | 92 | 0.320 |
Why?
|
| Wilms Tumor | 1 | 2009 | 8 | 0.320 |
Why?
|
| Neurocytoma | 2 | 2015 | 2 | 0.310 |
Why?
|
| Hemangioblastoma | 2 | 2020 | 12 | 0.310 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2009 | 56 | 0.300 |
Why?
|
| Pathology | 1 | 2009 | 8 | 0.300 |
Why?
|
| Tracheal Stenosis | 2 | 2020 | 7 | 0.300 |
Why?
|
| Neurology | 1 | 2009 | 11 | 0.300 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 123 | 0.300 |
Why?
|
| Telomerase | 2 | 2020 | 38 | 0.300 |
Why?
|
| Biopsy | 6 | 2018 | 208 | 0.290 |
Why?
|
| Trachea | 2 | 2020 | 43 | 0.290 |
Why?
|
| Tomography, Optical Coherence | 3 | 2022 | 96 | 0.290 |
Why?
|
| Endometrial Neoplasms | 1 | 2010 | 189 | 0.290 |
Why?
|
| Nerve Tissue Proteins | 2 | 2014 | 154 | 0.290 |
Why?
|
| MicroRNAs | 3 | 2022 | 302 | 0.290 |
Why?
|
| Benzenesulfonates | 3 | 2021 | 18 | 0.280 |
Why?
|
| Imines | 3 | 2021 | 21 | 0.280 |
Why?
|
| Ovarian Neoplasms | 3 | 2020 | 607 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2019 | 275 | 0.280 |
Why?
|
| Rats | 12 | 2021 | 1590 | 0.270 |
Why?
|
| Child, Preschool | 7 | 2020 | 1174 | 0.270 |
Why?
|
| Oils, Volatile | 3 | 2012 | 4 | 0.270 |
Why?
|
| Cell Movement | 5 | 2021 | 376 | 0.260 |
Why?
|
| Membrane Proteins | 3 | 2019 | 485 | 0.260 |
Why?
|
| Receptors, Androgen | 2 | 2008 | 26 | 0.260 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2016 | 166 | 0.260 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2018 | 26 | 0.250 |
Why?
|
| Receptors, GABA-A | 2 | 2017 | 18 | 0.240 |
Why?
|
| Tumor Cells, Cultured | 7 | 2017 | 314 | 0.240 |
Why?
|
| Lymphocytes | 2 | 2017 | 90 | 0.240 |
Why?
|
| Astrocytoma | 2 | 2018 | 37 | 0.240 |
Why?
|
| Disease Models, Animal | 12 | 2019 | 1508 | 0.240 |
Why?
|
| Tissue Engineering | 6 | 2021 | 152 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2020 | 554 | 0.230 |
Why?
|
| Spinal Neoplasms | 1 | 2005 | 40 | 0.220 |
Why?
|
| Spinal Cord Diseases | 1 | 2005 | 33 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2022 | 157 | 0.220 |
Why?
|
| Elastin | 2 | 2021 | 22 | 0.220 |
Why?
|
| Printing, Three-Dimensional | 3 | 2021 | 31 | 0.220 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2004 | 5 | 0.220 |
Why?
|
| Parotid Neoplasms | 1 | 2004 | 4 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 21 | 0.210 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 164 | 0.210 |
Why?
|
| Androstane-3,17-diol | 2 | 2017 | 9 | 0.210 |
Why?
|
| Tensile Strength | 2 | 2021 | 35 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 481 | 0.210 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 686 | 0.200 |
Why?
|
| Integrin alpha3 | 2 | 2021 | 18 | 0.200 |
Why?
|
| Nanoparticles | 3 | 2020 | 291 | 0.200 |
Why?
|
| Collagen | 2 | 2021 | 156 | 0.200 |
Why?
|
| Histones | 2 | 2021 | 96 | 0.200 |
Why?
|
| Lipoma | 1 | 2003 | 11 | 0.200 |
Why?
|
| Hydrogels | 2 | 2021 | 59 | 0.190 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2021 | 120 | 0.190 |
Why?
|
| Frontal Bone | 1 | 2002 | 5 | 0.190 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2002 | 5 | 0.190 |
Why?
|
| Transcription Factors | 3 | 2021 | 523 | 0.190 |
Why?
|
| Plant Oils | 2 | 2012 | 10 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2017 | 33 | 0.190 |
Why?
|
| Acetate-CoA Ligase | 1 | 2022 | 9 | 0.190 |
Why?
|
| Anesthesia, Epidural | 1 | 2022 | 7 | 0.190 |
Why?
|
| Skull Fractures | 1 | 2002 | 19 | 0.190 |
Why?
|
| Craniocerebral Trauma | 1 | 2002 | 27 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2017 | 120 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 347 | 0.180 |
Why?
|
| Mice, Nude | 6 | 2019 | 332 | 0.180 |
Why?
|
| Lenses | 1 | 2022 | 12 | 0.180 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2022 | 39 | 0.180 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 31 | 0.180 |
Why?
|
| Polyesters | 2 | 2020 | 35 | 0.180 |
Why?
|
| Microscopy | 1 | 2022 | 38 | 0.180 |
Why?
|
| Nanotubes | 1 | 2021 | 15 | 0.180 |
Why?
|
| Bioprinting | 1 | 2021 | 9 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 79 | 0.170 |
Why?
|
| Oklahoma | 3 | 2020 | 1055 | 0.170 |
Why?
|
| Fibrosis | 2 | 2020 | 143 | 0.170 |
Why?
|
| Intracellular Membranes | 1 | 2021 | 15 | 0.170 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 14 | 0.170 |
Why?
|
| Cell Plasticity | 1 | 2021 | 10 | 0.170 |
Why?
|
| Adenosine | 1 | 2021 | 33 | 0.170 |
Why?
|
| Calcium-Binding Proteins | 1 | 2021 | 62 | 0.170 |
Why?
|
| Brain Stem Neoplasms | 1 | 2020 | 12 | 0.170 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2015 | 75 | 0.170 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2021 | 30 | 0.170 |
Why?
|
| DNA Modification Methylases | 1 | 2020 | 14 | 0.170 |
Why?
|
| DNA Repair Enzymes | 1 | 2020 | 10 | 0.170 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2021 | 40 | 0.170 |
Why?
|
| Immunity, Innate | 3 | 2017 | 231 | 0.160 |
Why?
|
| Tenofovir | 1 | 2020 | 7 | 0.160 |
Why?
|
| Ritonavir | 1 | 2020 | 11 | 0.160 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 14 | 0.160 |
Why?
|
| Zinc | 1 | 2021 | 63 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 51 | 0.160 |
Why?
|
| Supratentorial Neoplasms | 1 | 2020 | 4 | 0.160 |
Why?
|
| Laparoscopy | 1 | 2022 | 156 | 0.160 |
Why?
|
| Child | 7 | 2020 | 2292 | 0.160 |
Why?
|
| Disease Progression | 6 | 2019 | 479 | 0.160 |
Why?
|
| Intracranial Aneurysm | 1 | 2021 | 63 | 0.160 |
Why?
|
| Zonula Occludens-1 Protein | 2 | 2018 | 17 | 0.160 |
Why?
|
| Lateral Ventricles | 1 | 2019 | 8 | 0.160 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 465 | 0.160 |
Why?
|
| Sulfhydryl Compounds | 1 | 2020 | 30 | 0.160 |
Why?
|
| Kidney Diseases | 1 | 2020 | 61 | 0.160 |
Why?
|
| Integrin beta1 | 1 | 2019 | 15 | 0.160 |
Why?
|
| Bone Regeneration | 1 | 2020 | 18 | 0.160 |
Why?
|
| Corpus Callosum | 1 | 2019 | 20 | 0.160 |
Why?
|
| Tendons | 1 | 2020 | 28 | 0.160 |
Why?
|
| Skull | 1 | 2020 | 41 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 163 | 0.150 |
Why?
|
| Survival Rate | 5 | 2021 | 432 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 48 | 0.150 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 379 | 0.150 |
Why?
|
| Deoxycytidine | 1 | 2019 | 67 | 0.150 |
Why?
|
| Cerebral Aqueduct | 1 | 2019 | 4 | 0.150 |
Why?
|
| Inferior Colliculi | 1 | 2019 | 4 | 0.150 |
Why?
|
| Polyglycolic Acid | 2 | 2010 | 38 | 0.150 |
Why?
|
| Neovascularization, Physiologic | 2 | 2010 | 124 | 0.150 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2019 | 6 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2020 | 78 | 0.150 |
Why?
|
| Models, Cardiovascular | 1 | 2019 | 47 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2020 | 152 | 0.150 |
Why?
|
| Neoplasm Staging | 5 | 2021 | 480 | 0.150 |
Why?
|
| Patient Positioning | 1 | 2019 | 23 | 0.150 |
Why?
|
| Cell Differentiation | 3 | 2017 | 427 | 0.150 |
Why?
|
| Glycosaminoglycans | 1 | 2019 | 55 | 0.150 |
Why?
|
| Anti-Infective Agents | 1 | 2020 | 78 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2018 | 20 | 0.150 |
Why?
|
| Lactic Acid | 2 | 2010 | 94 | 0.150 |
Why?
|
| Lymphangioma | 1 | 2018 | 3 | 0.140 |
Why?
|
| Metal Nanoparticles | 1 | 2020 | 137 | 0.140 |
Why?
|
| Hemangioma | 1 | 2018 | 8 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 15 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 105 | 0.140 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2018 | 15 | 0.140 |
Why?
|
| DNA Mutational Analysis | 3 | 2013 | 93 | 0.140 |
Why?
|
| Cell Communication | 1 | 2019 | 68 | 0.140 |
Why?
|
| Arteriovenous Malformations | 1 | 2018 | 16 | 0.140 |
Why?
|
| Absorbable Implants | 1 | 2018 | 16 | 0.140 |
Why?
|
| Claudin-1 | 1 | 2018 | 7 | 0.140 |
Why?
|
| Cysts | 1 | 2018 | 23 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 170 | 0.140 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 2 | 0.140 |
Why?
|
| Nanofibers | 1 | 2018 | 23 | 0.140 |
Why?
|
| HIV Infections | 1 | 2020 | 165 | 0.140 |
Why?
|
| Computer Simulation | 1 | 2019 | 238 | 0.140 |
Why?
|
| Anabolic Agents | 1 | 2017 | 12 | 0.140 |
Why?
|
| Interleukin-18 | 1 | 2017 | 18 | 0.140 |
Why?
|
| Neuroma, Acoustic | 1 | 2018 | 23 | 0.140 |
Why?
|
| Cell Survival | 6 | 2019 | 419 | 0.140 |
Why?
|
| Lysophospholipids | 1 | 2018 | 51 | 0.130 |
Why?
|
| ErbB Receptors | 2 | 2017 | 100 | 0.130 |
Why?
|
| Cell Membrane | 1 | 2019 | 268 | 0.130 |
Why?
|
| Transcriptome | 1 | 2019 | 232 | 0.130 |
Why?
|
| Gene Expression | 3 | 2019 | 417 | 0.130 |
Why?
|
| Disulfiram | 1 | 2017 | 4 | 0.130 |
Why?
|
| Vimentin | 3 | 2011 | 28 | 0.130 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2017 | 4 | 0.130 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2017 | 2 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 2 | 2017 | 141 | 0.130 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 43 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 14 | 0.130 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 18 | 0.130 |
Why?
|
| Prodrugs | 1 | 2017 | 30 | 0.130 |
Why?
|
| Thymus Gland | 1 | 2017 | 54 | 0.130 |
Why?
|
| Frankincense | 1 | 2016 | 1 | 0.130 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2017 | 72 | 0.130 |
Why?
|
| Gingiva | 1 | 2016 | 8 | 0.130 |
Why?
|
| Sirolimus | 1 | 2017 | 76 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 39 | 0.130 |
Why?
|
| Legionnaires' Disease | 1 | 2016 | 1 | 0.130 |
Why?
|
| Anticarcinogenic Agents | 1 | 2016 | 16 | 0.120 |
Why?
|
| RNA, Messenger | 2 | 2019 | 668 | 0.120 |
Why?
|
| Cauda Equina | 1 | 2016 | 5 | 0.120 |
Why?
|
| Ganglia | 1 | 2016 | 9 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 108 | 0.120 |
Why?
|
| Choristoma | 1 | 2016 | 7 | 0.120 |
Why?
|
| Macrophages | 1 | 2019 | 305 | 0.120 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 18 | 0.120 |
Why?
|
| Low Back Pain | 1 | 2016 | 29 | 0.120 |
Why?
|
| Eye Proteins | 1 | 2017 | 207 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2016 | 108 | 0.120 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 109 | 0.120 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2015 | 8 | 0.120 |
Why?
|
| Down-Regulation | 2 | 2017 | 202 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 485 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 1659 | 0.120 |
Why?
|
| Resins, Plant | 2 | 2012 | 3 | 0.120 |
Why?
|
| Infant | 4 | 2014 | 1026 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2014 | 2426 | 0.120 |
Why?
|
| Inflammation | 2 | 2017 | 668 | 0.120 |
Why?
|
| Sarcoma | 1 | 2015 | 29 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2015 | 9 | 0.110 |
Why?
|
| Adolescent | 6 | 2019 | 3198 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2015 | 81 | 0.110 |
Why?
|
| Monocytes | 1 | 2016 | 135 | 0.110 |
Why?
|
| Complement C3 | 1 | 2015 | 21 | 0.110 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2014 | 3 | 0.110 |
Why?
|
| Guided Tissue Regeneration | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cranial Irradiation | 1 | 2014 | 12 | 0.110 |
Why?
|
| Spheroids, Cellular | 3 | 2021 | 53 | 0.110 |
Why?
|
| Re-Epithelialization | 1 | 2014 | 5 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 301 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 63 | 0.110 |
Why?
|
| Muscles | 3 | 2022 | 73 | 0.110 |
Why?
|
| Mucous Membrane | 1 | 2014 | 28 | 0.110 |
Why?
|
| Endothelin-1 | 1 | 2014 | 10 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2014 | 28 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 31 | 0.110 |
Why?
|
| Phosphorylation | 4 | 2019 | 585 | 0.110 |
Why?
|
| Recombination, Genetic | 1 | 2014 | 64 | 0.110 |
Why?
|
| Aging | 2 | 2014 | 1019 | 0.110 |
Why?
|
| Spinal Diseases | 1 | 2015 | 43 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 126 | 0.110 |
Why?
|
| Mesenchymoma | 1 | 2014 | 1 | 0.110 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2014 | 2 | 0.110 |
Why?
|
| Ganglioneuroma | 1 | 2014 | 4 | 0.110 |
Why?
|
| Tongue Neoplasms | 1 | 2014 | 6 | 0.110 |
Why?
|
| Endothelial Cells | 4 | 2010 | 373 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 114 | 0.110 |
Why?
|
| Autocrine Communication | 1 | 2013 | 7 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 190 | 0.100 |
Why?
|
| Liver | 2 | 2019 | 471 | 0.100 |
Why?
|
| Paracrine Communication | 1 | 2013 | 17 | 0.100 |
Why?
|
| Growth Hormone | 1 | 2014 | 103 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2021 | 288 | 0.100 |
Why?
|
| Polymers | 2 | 2020 | 118 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2014 | 87 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 6 | 0.100 |
Why?
|
| Biomechanical Phenomena | 3 | 2021 | 182 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 28 | 0.100 |
Why?
|
| Plant Gums | 1 | 2012 | 3 | 0.100 |
Why?
|
| Necrosis | 3 | 2021 | 85 | 0.100 |
Why?
|
| Mice, Transgenic | 4 | 2017 | 513 | 0.100 |
Why?
|
| Brain Diseases | 1 | 2013 | 36 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2021 | 2638 | 0.100 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 28 | 0.100 |
Why?
|
| Cytogenetics | 1 | 2012 | 5 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2017 | 677 | 0.090 |
Why?
|
| Young Adult | 5 | 2019 | 2841 | 0.090 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 37 | 0.090 |
Why?
|
| Needles | 2 | 2022 | 26 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 179 | 0.090 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2011 | 1 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 82 | 0.090 |
Why?
|
| Dideoxynucleosides | 1 | 2011 | 12 | 0.090 |
Why?
|
| Heart Rate | 2 | 2010 | 382 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2012 | 83 | 0.090 |
Why?
|
| Nitrogen Oxides | 2 | 2021 | 41 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 130 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 74 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 107 | 0.080 |
Why?
|
| Meningeal Neoplasms | 1 | 2011 | 73 | 0.080 |
Why?
|
| Vena Cava, Superior | 1 | 2010 | 27 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 100 | 0.080 |
Why?
|
| Heart Conduction System | 2 | 2010 | 270 | 0.080 |
Why?
|
| Thoracic Vertebrae | 2 | 2015 | 70 | 0.080 |
Why?
|
| S100 Proteins | 2 | 2013 | 6 | 0.080 |
Why?
|
| Students, Medical | 1 | 2012 | 102 | 0.080 |
Why?
|
| Ganglia, Autonomic | 1 | 2010 | 55 | 0.080 |
Why?
|
| Epithelial Cells | 2 | 2017 | 265 | 0.080 |
Why?
|
| Aorta, Thoracic | 1 | 2010 | 55 | 0.080 |
Why?
|
| RNA, Small Interfering | 3 | 2020 | 198 | 0.080 |
Why?
|
| Action Potentials | 1 | 2010 | 196 | 0.080 |
Why?
|
| Bronchoscopy | 1 | 2010 | 35 | 0.080 |
Why?
|
| Cystitis | 1 | 2009 | 11 | 0.080 |
Why?
|
| Cryptorchidism | 1 | 2009 | 10 | 0.080 |
Why?
|
| Gold | 2 | 2021 | 137 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2009 | 39 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 328 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 634 | 0.080 |
Why?
|
| Materials Testing | 3 | 2020 | 89 | 0.080 |
Why?
|
| Leukocytes | 1 | 2009 | 72 | 0.080 |
Why?
|
| Cell Cycle | 3 | 2019 | 163 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 787 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 466 | 0.070 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 36 | 0.070 |
Why?
|
| Models, Biological | 3 | 2019 | 469 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 2 | 2019 | 97 | 0.070 |
Why?
|
| Stromal Cells | 2 | 2006 | 62 | 0.070 |
Why?
|
| Heme Oxygenase-1 | 2 | 2020 | 36 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2009 | 62 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 54 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2010 | 515 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 64 | 0.070 |
Why?
|
| 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) | 1 | 2008 | 1 | 0.070 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2008 | 3 | 0.070 |
Why?
|
| Astrocytes | 2 | 2014 | 80 | 0.070 |
Why?
|
| Urogenital System | 1 | 2008 | 5 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2012 | 250 | 0.070 |
Why?
|
| Multienzyme Complexes | 1 | 2008 | 29 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2021 | 270 | 0.070 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 2008 | 3 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 98 | 0.070 |
Why?
|
| Health Education | 1 | 2009 | 75 | 0.070 |
Why?
|
| Prostaglandin D2 | 1 | 2008 | 6 | 0.070 |
Why?
|
| X-Ray Microtomography | 2 | 2020 | 33 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2019 | 110 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2008 | 120 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 166 | 0.070 |
Why?
|
| Heterografts | 2 | 2018 | 66 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2009 | 98 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 236 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2008 | 96 | 0.070 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 90 | 0.070 |
Why?
|
| Neoplasms | 1 | 2017 | 874 | 0.070 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2007 | 12 | 0.070 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2007 | 25 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2013 | 104 | 0.070 |
Why?
|
| Heart Atria | 1 | 2008 | 177 | 0.070 |
Why?
|
| Autonomic Nervous System | 1 | 2008 | 118 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 134 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2017 | 106 | 0.060 |
Why?
|
| Amyloid beta-Peptides | 1 | 2007 | 49 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2017 | 58 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2019 | 55 | 0.060 |
Why?
|
| Prostatic Diseases | 1 | 2006 | 3 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 66 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2021 | 247 | 0.060 |
Why?
|
| In Vitro Techniques | 2 | 2017 | 242 | 0.060 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2005 | 7 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2017 | 292 | 0.060 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2005 | 8 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 94 | 0.060 |
Why?
|
| Drug Design | 1 | 2006 | 63 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2016 | 190 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 78 | 0.060 |
Why?
|
| Dogs | 3 | 2010 | 510 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2004 | 21 | 0.060 |
Why?
|
| Estradiol | 2 | 2019 | 176 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 251 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2004 | 67 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 464 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 270 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 2015 | 60 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 1032 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2008 | 404 | 0.050 |
Why?
|
| Permeability | 2 | 2017 | 61 | 0.050 |
Why?
|
| Synucleins | 1 | 2003 | 1 | 0.050 |
Why?
|
| beta-Synuclein | 1 | 2003 | 1 | 0.050 |
Why?
|
| gamma-Synuclein | 1 | 2003 | 2 | 0.050 |
Why?
|
| alpha-Synuclein | 1 | 2003 | 5 | 0.050 |
Why?
|
| Cystectomy | 2 | 2014 | 104 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2003 | 17 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 94 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2017 | 344 | 0.050 |
Why?
|
| Dynamin II | 1 | 2022 | 13 | 0.050 |
Why?
|
| Tumor Necrosis Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 21 | 0.050 |
Why?
|
| Dextrans | 1 | 2022 | 23 | 0.050 |
Why?
|
| Syndecan-1 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Epidural Space | 1 | 2022 | 11 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2022 | 42 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2022 | 8 | 0.050 |
Why?
|
| Esophagitis, Peptic | 1 | 2002 | 5 | 0.050 |
Why?
|
| Antacids | 1 | 2002 | 6 | 0.050 |
Why?
|
| Calcium Carbonate | 1 | 2002 | 6 | 0.050 |
Why?
|
| Computers | 1 | 2022 | 30 | 0.050 |
Why?
|
| Heartburn | 1 | 2002 | 26 | 0.050 |
Why?
|
| Craniotomy | 1 | 2002 | 61 | 0.050 |
Why?
|
| Cell Line | 3 | 2009 | 700 | 0.050 |
Why?
|
| Fourier Analysis | 1 | 2022 | 31 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2022 | 38 | 0.050 |
Why?
|
| Postprandial Period | 1 | 2002 | 51 | 0.050 |
Why?
|
| Nerve Regeneration | 1 | 2021 | 12 | 0.040 |
Why?
|
| Gelatin | 1 | 2021 | 11 | 0.040 |
Why?
|
| Weight-Bearing | 1 | 2021 | 43 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 70 | 0.040 |
Why?
|
| Chromosomes | 1 | 2022 | 59 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2018 | 404 | 0.040 |
Why?
|
| Axons | 1 | 2021 | 30 | 0.040 |
Why?
|
| Thromboplastin | 1 | 2021 | 28 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 32 | 0.040 |
Why?
|
| Anisotropy | 1 | 2021 | 28 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2021 | 65 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 95 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 144 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 220 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 226 | 0.040 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2020 | 3 | 0.040 |
Why?
|
| Inhibins | 1 | 2020 | 8 | 0.040 |
Why?
|
| Receptors, Somatostatin | 1 | 2020 | 8 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2022 | 254 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 36 | 0.040 |
Why?
|
| Rheology | 1 | 2020 | 22 | 0.040 |
Why?
|
| Septum Pellucidum | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cross-Linking Reagents | 1 | 2020 | 43 | 0.040 |
Why?
|
| Dihydrotestosterone | 2 | 2010 | 9 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 32 | 0.040 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.040 |
Why?
|
| Chickens | 1 | 2019 | 62 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2019 | 58 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2019 | 44 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 139 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2020 | 60 | 0.040 |
Why?
|
| Pressure | 1 | 2020 | 90 | 0.040 |
Why?
|
| Fish Oils | 1 | 2019 | 12 | 0.040 |
Why?
|
| Rabbits | 1 | 2020 | 278 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 180 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 34 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 36 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 149 | 0.040 |
Why?
|
| Biotinylation | 1 | 2019 | 19 | 0.040 |
Why?
|
| Liposomes | 1 | 2020 | 145 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 194 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2020 | 97 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 22 | 0.040 |
Why?
|
| Chemokine CXCL5 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Microvessels | 1 | 2019 | 86 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2021 | 163 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 431 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 122 | 0.040 |
Why?
|
| Solute Carrier Organic Anion Transporter Family Member 1B3 | 1 | 2019 | 21 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 146 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 79 | 0.040 |
Why?
|
| Cerebellum | 1 | 2019 | 41 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 118 | 0.040 |
Why?
|
| Surface Properties | 1 | 2019 | 134 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 52 | 0.040 |
Why?
|
| White Matter | 1 | 2019 | 90 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 319 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 186 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2019 | 90 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 212 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 2018 | 13 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2019 | 202 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 382 | 0.040 |
Why?
|
| Antioxidants | 1 | 2020 | 224 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2020 | 206 | 0.030 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2017 | 5 | 0.030 |
Why?
|
| Hexokinase | 1 | 2018 | 16 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2018 | 21 | 0.030 |
Why?
|
| Sheep | 1 | 2018 | 100 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 35 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2017 | 20 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2018 | 69 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 2017 | 22 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 59 | 0.030 |
Why?
|
| Peptides | 1 | 2020 | 296 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 43 | 0.030 |
Why?
|
| Carbon-Sulfur Lyases | 1 | 2017 | 16 | 0.030 |
Why?
|
| Glycolysis | 1 | 2018 | 96 | 0.030 |
Why?
|
| Dinoprost | 2 | 2008 | 9 | 0.030 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2017 | 7 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2017 | 56 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 194 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2017 | 8 | 0.030 |
Why?
|
| Annexin A5 | 1 | 2017 | 24 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 15 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2020 | 339 | 0.030 |
Why?
|
| Cell Separation | 1 | 2017 | 57 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2017 | 53 | 0.030 |
Why?
|
| Genome, Human | 1 | 2017 | 70 | 0.030 |
Why?
|
| Gene Order | 1 | 2016 | 10 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 555 | 0.030 |
Why?
|
| Triterpenes | 1 | 2016 | 9 | 0.030 |
Why?
|
| Pyridazines | 1 | 2016 | 8 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 231 | 0.030 |
Why?
|
| Legionella pneumophila | 1 | 2016 | 5 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 25 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 273 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 169 | 0.030 |
Why?
|
| Transgenes | 1 | 2016 | 63 | 0.030 |
Why?
|
| Imidazoles | 1 | 2016 | 63 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 233 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 292 | 0.030 |
Why?
|
| Genomics | 1 | 2017 | 125 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2016 | 118 | 0.030 |
Why?
|
| Laminectomy | 1 | 2016 | 31 | 0.030 |
Why?
|
| Time Factors | 2 | 2011 | 1615 | 0.030 |
Why?
|
| Decorin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Sulfatases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 137 | 0.030 |
Why?
|
| Receptors, Complement | 1 | 2015 | 6 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2015 | 174 | 0.030 |
Why?
|
| Lumbar Vertebrae | 1 | 2016 | 129 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 18 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 875 | 0.030 |
Why?
|
| Rats, Mutant Strains | 1 | 2014 | 16 | 0.030 |
Why?
|
| Brain Edema | 1 | 2014 | 21 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2014 | 34 | 0.030 |
Why?
|
| Dwarfism | 1 | 2014 | 27 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2014 | 26 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 68 | 0.030 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2013 | 2 | 0.030 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2013 | 2 | 0.030 |
Why?
|
| MART-1 Antigen | 1 | 2013 | 3 | 0.030 |
Why?
|
| Monophenol Monooxygenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Isonicotinic Acids | 1 | 2013 | 1 | 0.030 |
Why?
|
| Picrotoxin | 1 | 2013 | 1 | 0.030 |
Why?
|
| GABA Antagonists | 1 | 2013 | 4 | 0.030 |
Why?
|
| GABA Agonists | 1 | 2013 | 4 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 21 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 24 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2015 | 123 | 0.030 |
Why?
|
| Quinazolines | 1 | 2013 | 32 | 0.030 |
Why?
|
| Retina | 1 | 2017 | 445 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2013 | 71 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 8 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 15 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2012 | 27 | 0.020 |
Why?
|
| Dermatomyositis | 1 | 2013 | 60 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2013 | 50 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 119 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2012 | 185 | 0.020 |
Why?
|
| United States | 1 | 2018 | 2226 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2011 | 29 | 0.020 |
Why?
|
| CD56 Antigen | 1 | 2011 | 1 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2011 | 22 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2010 | 6 | 0.020 |
Why?
|
| Retinoid X Receptors | 1 | 2010 | 24 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2010 | 27 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 1022 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 41 | 0.020 |
Why?
|
| Bronchoscopes | 1 | 2010 | 2 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 82 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 257 | 0.020 |
Why?
|
| Puberty | 1 | 2009 | 13 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2009 | 56 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 218 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 119 | 0.020 |
Why?
|
| Computational Biology | 1 | 2010 | 156 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2008 | 7 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 57 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 185 | 0.020 |
Why?
|
| Receptors, Prostaglandin | 1 | 2008 | 1 | 0.020 |
Why?
|
| Chromones | 1 | 2008 | 11 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 103 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2008 | 82 | 0.020 |
Why?
|
| Morpholines | 1 | 2008 | 28 | 0.020 |
Why?
|
| Urea | 1 | 2008 | 16 | 0.020 |
Why?
|
| beta Catenin | 1 | 2008 | 66 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 73 | 0.020 |
Why?
|
| Species Specificity | 1 | 2008 | 195 | 0.020 |
Why?
|
| Particle Size | 1 | 2008 | 105 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 135 | 0.020 |
Why?
|
| Cytokines | 1 | 2009 | 451 | 0.020 |
Why?
|
| Neuroglia | 1 | 2007 | 30 | 0.020 |
Why?
|
| Wound Healing | 1 | 2008 | 126 | 0.020 |
Why?
|
| Endosomes | 1 | 2007 | 53 | 0.020 |
Why?
|
| Immunization | 1 | 2007 | 121 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2007 | 108 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 125 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2007 | 97 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2008 | 223 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2006 | 24 | 0.010 |
Why?
|
| Testosterone | 1 | 2006 | 74 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 285 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 209 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 737 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2004 | 15 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2004 | 74 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2007 | 225 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 137 | 0.010 |
Why?
|
| Breast | 1 | 2004 | 52 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2004 | 114 | 0.010 |
Why?
|
| Dosage Forms | 1 | 2002 | 5 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2002 | 28 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2002 | 270 | 0.010 |
Why?
|